
The FDA approved adrabetadex for infantile-onset NPC based on a 55% lower risk of death vs external controls, with a boxed warning for hearing loss.
Tooth pain, dental disease, and poor access to dental care adversely affect how children perform in school and are associated with increased school absences and missed parental days of work.






